2024
Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure
Mezzacappa C, Kim N, Vutien P, Kaplan D, Ioannou G, Taddei T. Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure. JAMA Network Open 2024, 7: e2420963. PMID: 38985470, PMCID: PMC11238019, DOI: 10.1001/jamanetworkopen.2024.20963.Peer-Reviewed Original ResearchConceptsHepatitis C virus cureHepatitis C virusAssociated with improved overall survivalHepatocellular carcinoma diagnosisEarly-stage hepatocellular carcinomaImproved overall survivalOverall survivalHepatocellular carcinomaFollow-upHCC screeningCurative treatmentCumulative incidence of hepatocellular carcinomaDirect-acting antiviral (DAA) therapyCohort studyVeterans Affairs health care systemIncidence of hepatocellular carcinomaRisk of hepatocellular carcinomaCohort study of personsHepatitis C virus cirrhosisDiagnosis of hepatocellular carcinomaLikelihood of curative treatmentYears of follow-upHealth care systemHepatocellular carcinoma screeningHCV-related cirrhosis
2023
The role of routine biopsy of the background liver in the management of hepatocellular carcinoma
Lee S, Ahmed M, Taddei T, Jain D. The role of routine biopsy of the background liver in the management of hepatocellular carcinoma. Human Pathology 2023, 138: 18-23. PMID: 37236406, DOI: 10.1016/j.humpath.2023.05.009.Peer-Reviewed Original ResearchMeSH KeywordsBiopsyCarcinoma, HepatocellularFemaleHumansLiver CirrhosisLiver NeoplasmsMaleMiddle AgedConceptsLiver biopsyEarly HCC stagesHepatocellular carcinoma managementLarge university hospitalSeparate biopsiesCirrhosis statusClinical characteristicsClinical suspicionMedian ageEarly diseasePathology databaseRoutine biopsyHCC stageBiopsy resultsHCC patientsParenchymal findingsUniversity HospitalBackground liverHepatocellular carcinomaNontumoral liverHCC biopsiesBiopsyPatientsCirrhosisLiverAASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal A, Llovet J, Yarchoan M, Mehta N, Heimbach J, Dawson L, Jou J, Kulik L, Agopian V, Marrero J, Mendiratta-Lala M, Brown D, Rilling W, Goyal L, Wei A, Taddei T. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023, 78: 1922-1965. PMID: 37199193, PMCID: PMC10663390, DOI: 10.1097/hep.0000000000000466.Peer-Reviewed Original Research
2022
Alternative HCC prognostic biomarkers and use of artificial intelligence in the management of HCC
Jaffe A, Taddei T, Giannini E, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Alternative HCC prognostic biomarkers and use of artificial intelligence in the management of HCC. Liver International 2022, 43: 258-259. PMID: 36426717, DOI: 10.1111/liv.15482.Peer-Reviewed Original ResearchAttacking the public health crisis of hepatocellular carcinoma at its roots
Lee HM, Lidofsky SD, Taddei TH, Townshend‐Bulson L. Attacking the public health crisis of hepatocellular carcinoma at its roots. Hepatology 2022, 77: 1456-1459. PMID: 35989555, PMCID: PMC10026951, DOI: 10.1002/hep.32741.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularHepatitis B, ChronicHumansLiver NeoplasmsNon-alcoholic Fatty Liver DiseasePublic HealthRisk FactorsConceptsHepatitis B virusLiver diseasePublic health crisisHepatocellular carcinomaChronic hepatitis B virusAlcohol-related liver diseaseNonalcoholic fatty liver diseaseChronic liver diseaseFatty liver diseasePrincipal risk factorsCancer-related deathSignificant mortality ratePrevention of HCCHealth crisisViral hepatitisTreatment advancesB virusRisk factorsCurable stageCommon causeRisk populationsHCC detectionRisk individualsMortality rateSurveillance programHolistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook
Jaffe A, Taddei TH, Giannini EG, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International 2022, 42: 2607-2619. PMID: 36161463, PMCID: PMC10878125, DOI: 10.1111/liv.15432.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularGastroenterologistsHepatitis B, ChronicHumansLiver CirrhosisLiver NeoplasmsNeoplasm Recurrence, LocalRisk FactorsConceptsLiver diseaseHepatocellular carcinomaLiver functionRisk factorsRelevant prognostic roleChronic hepatitis BResidual liver functionChronic liver diseaseManagement of patientsCare of patientsCommon risk factorsAppropriate surveillance strategiesSuccessful cancer treatmentC infectionCommon complicationHepatitis BMetabolic syndromePrognostic roleSignificant morbidityLongitudinal careCurrent careCancer recurrenceHCC managementLiver cancerHCC treatmentPatterns of Care Utilization and Hepatocellular Carcinoma Surveillance: Tracking Care Across the Pandemic
Serper M, Tapper EB, Kaplan DE, Taddei TH, Mahmud N. Patterns of Care Utilization and Hepatocellular Carcinoma Surveillance: Tracking Care Across the Pandemic. The American Journal Of Gastroenterology 2022, 118: 294-303. PMID: 36114778, PMCID: PMC9898115, DOI: 10.14309/ajg.0000000000002011.Peer-Reviewed Original ResearchConceptsOutpatient primary care providerHepatocellular carcinoma surveillancePrimary care providersHCC surveillanceCare providersHCC surveillance ratesGastroenterology/hepatologyFacility-level variablesCirrhosis cohortPatient demographicsClinical factorsTotal cohortCare utilizationNational cohortOutpatient utilizationSpecialty careInpatient careMultivariable modelPercentage of timePopulation-based approachSurveillance ratesAppointment ratesAdjusted modelVisit ratesCoronavirus diseaseUsing Telemedicine to Facilitate Patient Communication and Treatment Decision-Making Following Multidisciplinary Tumor Board Review for Patients with Hepatocellular Carcinoma
Choi DT, Sada YH, Sansgiry S, Kaplan DE, Taddei TH, Aguilar JK, Strayhorn M, Hernaez R, Davila JA. Using Telemedicine to Facilitate Patient Communication and Treatment Decision-Making Following Multidisciplinary Tumor Board Review for Patients with Hepatocellular Carcinoma. Journal Of Gastrointestinal Cancer 2022, 54: 623-631. PMID: 35773376, PMCID: PMC9247952, DOI: 10.1007/s12029-022-00844-w.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularCommunicationCOVID-19HumansLiver NeoplasmsPandemicsPilot ProjectsTelemedicineConceptsVA Medical CenterHepatocellular carcinomaTreatment recommendationsPerson visitsPatient's perspectiveTumor board recommendationsTumor board reviewCancer care deliveryUse of telemedicineDelivery of careTypes of cancerMTB recommendationsTelemedicine visitsTelemedicine interventionsTreatment referralMedical CenterSemi-structured qualitative interviewsPatientsPilot interventionCare deliveryPatient communicationCancer informationPilot studyAcceptable alternativeIntervention developmentQuality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases
Asrani SK, Ghabril MS, Kuo A, Merriman RB, Morgan T, Parikh ND, Ovchinsky N, Kanwal F, Volk ML, Ho C, Serper M, Mehta S, Agopian V, Cabrera R, Chernyak V, El‐Serag H, Heimbach J, Ioannou GN, Kaplan D, Marrero J, Mehta N, Singal A, Salem R, Taddei T, Walling AM, Tapper EB. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022, 75: 1289-1299. PMID: 34778999, DOI: 10.1002/hep.32240.Peer-Reviewed Original ResearchMeSH KeywordsAlpha-FetoproteinsBenchmarkingCarcinoma, HepatocellularHumansLiver NeoplasmsQuality Indicators, Health CareUnited StatesConceptsPatient-reported outcomesHigh-risk populationHCC careCare continuumBarcelona Clinic Liver Cancer (BCLC) stagingData System (BI-RADS) 4 lesionsBurden of HCCLiver transplantation candidacyTumor board reviewLiver Imaging ReportingFear of treatmentStructured scoping reviewExplicit quality measuresAmerican AssociationTransplantation candidacyBest individual treatmentPalliative therapyGuideline recommendationsLiver diseaseAFP elevationAppropriate referralTreatment optionsTreatment recommendationsCancer stagingOutcome measuresMR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features
Petukhova-Greenstein A, Zeevi T, Yang J, Chai N, DiDomenico P, Deng Y, Ciarleglio M, Haider SP, Onyiuke I, Malpani R, Lin M, Kucukkaya AS, Gottwald LA, Gebauer B, Revzin M, Onofrey J, Staib L, Gunabushanam G, Taddei T, Chapiro J. MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features. Journal Of Vascular And Interventional Radiology 2022, 33: 814-824.e3. PMID: 35460887, PMCID: PMC9335926, DOI: 10.1016/j.jvir.2022.04.006.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCarcinoma, HepatocellularCatheter AblationContrast MediaHumansLiver NeoplasmsMagnetic Resonance ImagingRetrospective StudiesConceptsProgression-free survivalPoor progression-free survivalLiver Imaging ReportingHepatocellular carcinomaMR imaging biomarkersRadiomics signatureRadiofrequency ablationRadiomic featuresImaging biomarkersImaging ReportingFirst follow-up imagingMedian progression-free survivalRF ablationEarly-stage hepatocellular carcinomaPretreatment magnetic resonanceFirst-line treatmentMultifocal hepatocellular carcinomaSelection operator Cox regression modelTherapy-naïve patientsEarly-stage diseaseKaplan-Meier analysisCox regression modelLog-rank testFollow-up imagingPrediction of outcomeOptimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolizationOral Cyanobacteria and Hepatocellular Carcinoma
Hernandez BY, Zhu X, Risch HA, Lu L, Ma X, Irwin ML, Lim JK, Taddei TH, Pawlish KS, Stroup AM, Brown R, Wang Z, Wong LL, Yu H. Oral Cyanobacteria and Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2022, 31: 221-229. PMID: 34697061, PMCID: PMC8755591, DOI: 10.1158/1055-9965.epi-21-0804.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, HepatocellularCase-Control StudiesCyanobacteriaFemaleHumansLiver NeoplasmsMaleMiddle AgedMouthRisk FactorsUnited StatesConceptsHepatitis B virusHepatitis C virusHepatocellular carcinomaRisk factorsLiver diseaseHCC casesOral microbiomeU.S. case-control studyIndependent risk factorChronic liver diseaseFatty liver diseaseHCC risk factorsGut microbial alterationsType 2 diabetesCase-control studyLiver cancer developmentNSAID useAspirin useC virusB virusHCC riskNegative historyOral samplesSignificant associationCancer development
2021
Rates of decompensation, hepatocellular carcinoma and mortality in AMA‐negative primary biliary cholangitis cirrhosis
John BV, Dahman B, Deng Y, Khakoo NS, Taddei TH, Kaplan DE, Levy C. Rates of decompensation, hepatocellular carcinoma and mortality in AMA‐negative primary biliary cholangitis cirrhosis. Liver International 2021, 42: 384-393. PMID: 34614294, PMCID: PMC8810619, DOI: 10.1111/liv.15079.Peer-Reviewed Original ResearchMeSH KeywordsAutoantibodiesCarcinoma, HepatocellularCholangitisHumansLiver Cirrhosis, BiliaryLiver NeoplasmsMaleConceptsLiver-related deathAMA-negative PBCPBC cirrhosisHepatocellular carcinomaMale patientsAMA-positive patientsAMA-positive PBCLiver-related outcomesSimilar unadjusted ratesAnti-mitochondrial antibodiesSimilar ratesNumber of patientsVeterans Health AdministrationRate of decompensationDevelopment of deathUDCA responseOverall deathUnadjusted ratesCirrhosis diagnosisCirrhosisLarge cohortDecompensationPatientsHealth AdministrationNatural historyHepatocellular Carcinoma
Jain A, Mazer B, Deng Y, Ciarleglio M, Jain D, Taddei T, Zhang X. Hepatocellular Carcinoma. American Journal Of Clinical Pathology 2021, 157: 305-313. PMID: 34542582, DOI: 10.1093/ajcp/aqab125.Peer-Reviewed Original ResearchConceptsAnaplastic tumor cellsHepatocellular carcinomaNoncirrhotic liverVascular invasionHistologic patternCirrhotic liverTumor cellsClear cell subtypePathogenesis of HCCHigh histologic gradeLarger tumor sizeHigher tumor stageHigh tumor gradeHigh rateHepatitis BHepatitis CLiver diseaseTumor sizeHistologic gradeTumor stageTumor gradePathologic differencesHCC casesRetrospective analysisPathology archivesMale Sex Is Associated With Higher Rates of Liver‐Related Mortality in Primary Biliary Cholangitis and Cirrhosis
John BV, Aitcheson G, Schwartz KB, Khakoo NS, Dahman B, Deng Y, Goldberg D, Martin P, Taddei T, Levy C, Kaplan DE. Male Sex Is Associated With Higher Rates of Liver‐Related Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology 2021, 74: 879-891. PMID: 33636012, DOI: 10.1002/hep.31776.Peer-Reviewed Original ResearchConceptsPrimary biliary cholangitisLiver-related deathHepatocellular carcinomaBiliary cholangitisMale sexTime-updated Cox proportional hazards modelsCox proportional hazards modelUrsodeoxycholic acid responseLiver-related mortalityHigher unadjusted ratesRisk of deathVeterans Health AdministrationProportional hazards modelAssociation of sexImpact of sexPBC cirrhosisMale patientsUnadjusted ratesWorse outcomesTotal bilirubinCirrhosisLarge cohortHigh riskHazards modelTransplantationThe effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma
Sellers CM, Uhlig J, Ludwig JM, Pollak JS, Taddei TH, Stein SM, Lim JK, Kim HS. The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma. Cancer Medicine 2021, 10: 5395-5404. PMID: 34318618, PMCID: PMC8366096, DOI: 10.1002/cam4.3573.Peer-Reviewed Original ResearchConceptsChronic viral hepatitisViral hepatitisHepatocellular carcinomaMultivariable analysisMedian OSNLR groupHepatitis CKaplan-Meier overall survival curvesCox hazard proportional modelHigher median OSLow baseline NLROverall survival curvesTertiary care institutionBaseline NLRDecreased OSNonviral hepatitisHigh NLRInflammatory biomarkersLow NLRMultivariable adjustmentOverall survivalLymphocyte ratioPrognostic valueRetrospective studyPrognostic relevanceHNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas.
Patil PA, Taddei T, Jain D, Zhang X. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas. Archives Of Pathology & Laboratory Medicine 2021, 146: 220-226. PMID: 34086854, DOI: 10.5858/arpa.2020-0725-oa.Peer-Reviewed Original ResearchUrsodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis
John BV, Khakoo NS, Schwartz KB, Aitchenson G, Levy C, Dahman B, Deng Y, Goldberg DS, Martin P, Kaplan DE, Taddei TH. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. The American Journal Of Gastroenterology 2021, 116: 1913-1923. PMID: 33989225, PMCID: PMC8410631, DOI: 10.14309/ajg.0000000000001280.Peer-Reviewed Original ResearchConceptsLiver-related deathPrimary biliary cholangitisUDCA responseHepatic decompensationHepatocellular carcinomaUrsodeoxycholic acidUDCA respondersPortal hypertensionPartial respondersBiliary cholangitisTime-updated Cox proportional hazards modelsCox proportional hazards modelUrsodeoxycholic acid responseLiver-related mortalityRetrospective cohort studyProportional hazards modelPBC cirrhosisCompensated cirrhosisCohort studyMale patientsClinical benefitUnadjusted ratesCirrhosisReduced mortalityDecompensationChanges in Hepatocellular Carcinoma Surveillance and Risk Factors for Noncompletion in the Veterans Health Administration Cohort During the Coronavirus Disease 2019 Pandemic
Mahmud N, Kaplan DE, Goldberg DS, Taddei TH, Serper M. Changes in Hepatocellular Carcinoma Surveillance and Risk Factors for Noncompletion in the Veterans Health Administration Cohort During the Coronavirus Disease 2019 Pandemic. Gastroenterology 2021, 160: 2162-2164.e3. PMID: 33434604, PMCID: PMC8142896, DOI: 10.1053/j.gastro.2021.01.007.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularCOVID-19HumansLiver NeoplasmsRetrospective StudiesRisk FactorsSARS-CoV-2Veterans Health
2020
Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma.
Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Bräu N, Brown ST, Taddei TH, Justice AC, Lo Re V. Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 85: 530-534. PMID: 33185999, PMCID: PMC8353543, DOI: 10.1097/qai.0000000000002510.Peer-Reviewed Original ResearchConceptsSetting of HCCFIB-4Receiver-operating characteristic curveHepatocellular carcinomaHCC diagnosisPredictive valueVeterans Aging Cohort StudyEvidence of cirrhosisSetting of HIVAbsence of cirrhosisFIB-4 scoreFibrosis-4 indexIncident hepatocellular carcinomaMedical record reviewPrevalence of cirrhosisAging Cohort StudyCross-sectional studyCharacteristic curveNegative predictive valuePositive predictive valueCirrhosis statusCohort studyMechanisms of carcinogenesisRecord reviewPlatelet count